Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Secondary surgery extends OS in recurrent ovarian cancer

Key clinical point: Secondary cytoreductive surgery can improve overall survival in some patients with recurrent ovarian cancer.

Major finding: The median overall survival was 53.7 months with surgery plus chemotherapy and 46 months with chemotherapy alone (P = .02).

Study details: A randomized, phase 3 trial of 407 women with recurrent ovarian cancer who were platinum free for more than 6 months.

Disclosures: The study was sponsored by the AGO study group in collaboration with other oncology groups, Medac, and GlaxoSmithKline. Dr. du Bois disclosed relationships with several companies.


du Bois A et al. ASCO 2020, Abstract 6000.